Tiloram - instructions for use, doses, side effects, contraindications

Auxiliary substances (nucleus): lactose monohydrate (milk sugar) - 101.0 mg, microcrystalline cellulose - 45.0 mg, croscarmellose sodium - 9.0 mg, water 5.0 mg, povidone - K17 - 12.0 mg, magnesium stearate - 3.0 mg.

Auxiliary substances (membrane): hypromellose - 5.7 mg, macrogol-4000 - 1.4 mg, titanium dioxide - 2.8 mg, tropeolin-0 dye - 0.1 mg.

Description:

round, biconvex tablets, covered with a film coat from yellow to orange. On the fracture, two layers are visible: a film shell and an orange core, white or orange impregnations are allowed.

Pharmacotherapeutic group:antiviral immunostimulating means - inducer of the formation of interferons.

ATX: & nbsp

L.03.A.X Other immunostimulants

Pharmacodynamics:

A low molecular weight synthetic interferon inducer that stimulates the formation of alpha, beta and gamma interferons in the body. The main producers of interferon in response to the introduction of Tyloron are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils and granulocytes. After oral administration, the maximum production of interferon is determined in the sequence of the intestine - liver - blood after 4-24 hours. Tyloron has immunomodulatory and antiviral effect. In leukocytes, immunodepression, restores the ratio of T-suppressors and T-helpers. Effective against various viral infections, including against influenza viruses, other acute respiratory viral infections, hepatitis viruses and herpesviruses. The mechanism of antiviral action is associated with the inhibition of the translation of virus-specific proteins in infected cells, as a result of which the reproduction of viruses is suppressed.

Pharmacokinetics:

After oral administration, it is rapidly absorbed from the gastrointestinal tract. Bioavailability is 60%. About 80% of the drug binds to plasma proteins. The drug is practically unchanged through the intestine (70%) and through the kidneys (9%).The half-life is 48 hours. The drug is not biotransformed and does not accumulate in the body.

Indications:

Treatment and prevention of influenza, other acute respiratory viral infections (ARVI);

treatment of viral hepatitis A, B and C;

treatment of herpetic and cytomegalovirus infection;

in the complex therapy of infectious-allergic and viral encephalomyelitis (multiple sclerosis, leukoencephalitis, uveoencephalitis, etc.);

in the complex therapy of urogenital and respiratory chlamydia;

at integrated of therapy tuberculosis lungs.

Contraindications:

- hypersensitivity to tilorone and other components of the drug.

- period of pregnancy and lactation.

- Children under 18 years.

- hereditary lactose intolerance, lactase deficiency, glucose-galactose malabsorption.

Carefully:In the complex therapy of infectious-allergic and viral encephalomyelitis drug is used under the supervision of a doctor

Pregnancy and lactation:

Safety of use during pregnancy and lactation is not known.

The drug is contraindicated during pregnancy. If it is necessary to prescribe the drug during lactation, breastfeeding should be stopped.

Dosing and Administration:

Tyloron is taken orally after eating.

For the treatment of viral hepatitis A - 125 mg twice a day on the first day, then 125 mg after 48 hours. The course is 1.25 g.

For the treatment of acute hepatitis B - the first two days of 125 mg, then 125 mg after 48 hours, the course of treatment - 2 g. With prolonged hepatitis B - 125 mg twice a day on the first day, then 125 mg after 48 hours. The course of treatment - 2.5 g.

In chronic hepatitis B - the initial phase of treatment (2.5 g) - the first two days of 125 mg twice a day, then 125 mg after 48 hours. The continuation phase (from 1.25 g to 2.5 g), 125 mg per week. The course dose of tyloron from 3.75 g to 5 g, the duration of therapy is 3.5-6 months, depending on the results of biochemical, immunological, morphological studies, reflecting the degree of activity of the process.

In acute hepatitis C, 125 mg per day for the first 2 days of treatment, then 125 mg after 48 hours. The course of treatment is 2.5 g.

In chronic hepatitis C - the initial phase of treatment (2.5 g) - the first two days for 125 mg 2 times a day, then 125 mg after 48 hours. The continuation phase (2.5 g) of 125 mg per week. The course dose of tyloron - 5 g, the duration of therapy - 6 months, depending on the results of biochemical, immunological, morphological markers of activity of the process.

In the complex treatment of infectious-allergic and viral encephalomyelitis - 125-250 mg per day for the first 2 days of treatment, then 125 mg after 48 hours. The dose is set individually, the course of treatment is 3-4 weeks.

For treatment of influenza and other acute respiratory viral infections, 125 mg daily for the first 2 days of treatment, then 125 mg after 48 hours. The course is 750 mg.

For the prevention of influenza and other acute respiratory viral infections, 125 mg once a week for 6 weeks. The course is 750 mg.

For treatment of herpetic, cytomegalovirus infection - the first two days of 125 mg, then 48 hours after 125 mg. The course dose is 1.25 - 2.5 g.

With urogenital and respiratory chlamydia - the first two days of 125 mg, then 48 hours after 125 mg. Course dose -1.25 g.

With the complex therapy of pulmonary tuberculosis - 250 mg the first two days of treatment, then 125 mg after 48 hours. The course dose is 2.5 g.

Side effects:Allergic reactions, dyspeptic phenomena, short-term chills are possible.

Overdose:

Cases of drug overdose are not known.

Interaction:

Compatible with antibiotics and drugs traditional treatment of viral and bacterial diseases. Clinically significant interaction of Tyloron with antibiotics and traditional treatment of viral and bacterial diseases, alcohol was not detected.

Effect on the ability to drive transp. cf.and fur:

Data on the effect of the drug on the ability to drive by car and engage in other potentially dangerous activities that require increased concentration and speed of psychomotor reactions in the recommended doses are not available.

Form release / dosage:

Tablets, film-coated 125 mg.

Packaging:

By 6, 10, 12, 18, 20, 24 or 30 tablets in a contour mesh box made of polyvinylchloride film and aluminum foil printed lacquered.

By 6, 10, 12, 18, 20, 24, 30, 50 or 100 tablets in cans of polymer or cans of polyethylene terephthalate.

One jar or 1, 2, 3, 4, 5 or 10 contour mesh packages together with the instruction for use are placed in a cardboard package (bundle).

It is allowed to bundle 2 or 3 cardboard packages (packs) into a group package (shipping container) made of cardboard.

Storage conditions:

In the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiration date.

Terms of leave from pharmacies:Without recipe

Registration number:LP-002827

Date of registration:20.01.2015

The owner of the registration certificate:ATOLL, LLC ATOLL, LLC Russia

Manufacturer: & nbsp

OZONE, LLC Russia

Representation: & nbspOZONE LLC OZONE LLC Russia

Information update date: & nbsp29.08.2015

Illustrated instructions

Instructions

Tiloram (Tiloram)